Our study defines ex vivo SARS-CoV-2-specific T cells during primary and recall responses and provides key insights into CD8+ and CD4+ T cell responses in fully recovered and long COVID people, following SARS-CoV-2 infection and subsequent COVID-19 vaccination. This evidence concerns the gene CD8A and COVID-19.